Stock MDNA MEDICENNA THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Medicenna Therapeutics Corp.

Equities

MDNA

CA58490H1073

Market Closed - Toronto S.E.
Other stock markets
 03:59:59 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.85 CAD +22.84% Intraday chart for Medicenna Therapeutics Corp. +20.76% +578.57%
May. 22 Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum MT
May. 13 Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee
Medicenna Brief: Providing Update on its Presentations at the 2024 ASCO Annual Meeting
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.
Canadian Investment Regulatory Organization Trade Resumption - MDNA
Canadian Investment Regulatory Organization Trading Halt - MDNA
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding
Medicenna Therapeutics Up 13% After Flagging Presentations
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research
Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today
Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDNA Stock
  4. News Medicenna Therapeutics Corp.
  5. Other languages